In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7288-7296

  Burvenich, Ingrid ^a   Schoonooghe, Steve ^a   Cornelissen, Bart ^a   Blanckaert, Peter ^a   Coene, Elisabeth ^a   Cuvelier, Claude ^a   Mertens, Nico ^a   Slegers, Guido ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IODINE 123; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14C5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL ADHESION; CELL INVASION; COLON CARCINOMA; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COLONIC NEOPLASMS; FLOW CYTOMETRY; GAMMA CAMERAS; HT29 CELLS; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27144452013     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2503     Document Type: Article

References (40)

1. Grillo-Lopez AJ. Rituximab (Rituxan/MabThera): the first decade (1993-2003). Expert Rev Anticancer Ther 2003;3:767-79.
2. Grillo-Lopez AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2002;2:485-93.
3. Witzig TE. Zevalin (TM). Treatment of non-Hodgkin's lymphoma. Drugs Future 2002;27:563-8.
4. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodide (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-66.
5. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003;101:391-8.
6. 131I-labeled monoclonal antibodies. Cancer Res 1992;52:6036-44.
7. Behr TM, Sharkey RM, Juweid ME, et al. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med 1997;38:409-18.
8. Behr TM, Blumenthal RD, Memtsoudis S, et al. Cure of metastatic human colonic cancer in mice with radio-labeled monoclonal antibody fragments. Clin Cancer Res 2000;6:4900-7.
9. Gambhir SS, Czemin J, Schwimmer J, Silverman DH, Coleman RE, Phelps MEJ. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1-93S.
10. Nielsen UB, Adams GP, Weiner LM, James DM. Targeting of bivalent anti-erbB2 antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res 2000;60:6434-40.
11. Kobayashi H, Shirakawa K, Kawamoto S, et al. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). Cancer Res 2002;62:860-6.
12. Goldenberg DM, Nabi HA. Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med 1999;29:41-8.
13. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 2000;60:4804-11.
14. De Potter CR, Schelfhout AM, De Smet FH, et al. A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasion. Am J Pathol 1994;144:95-103.
15. Coene E, Schelfhout AM, De Ridder L, De Potter CR. Generation of a monoclonal antibody directed against a human cell substrate adhesion molecule and the expression of the antigen in human tissues. Hybridoma 1997;16:77-83.
16. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491-7.
17. Davies J, Warwick J, Totty N, Philp R, Helfrich M, Horton M. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 1989;109:1817-26.
18. Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, Gould VE. Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules. Am J Pathol 1991;139:787-99.
19. Pignatelli M, Cardillo MR, Hanby A, Stamp GW. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 1992;23:1159-66.
20. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124-38.
21. Lahorte CM, Bacher K, Burvenich I, et al. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo. J Nucl Med 2004;45:1065-73.
22. Fraker PJ, Speck JC, Jr. Protein and cell membrane iodinations with a sparingly soluble chloraamide,1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978;80:849-57.
23. Gridelli C. Targeted therapies in the treatment of non small cell lung cancer: reality and hopes. Curr Opin Oncol 2004;16:126-9.
24. Maione P, Rossi A, Airoma G, Ferrara C, Castaldo V, Gridelli C. The role of targeted therapy in non-small cell lung cancer. Crit Rev Oncol Hematol 2004;51:29-44.
25. Matzku S, Brocker EB, Bruggen J, Dippold WG, Tilgen W. Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines. Cancer Res 1986;46:3848-54.
26. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906-12.
27. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000;60:5237-43.
28. Zuckier LS, Berkowitz EZ, Sattenberg RJ, Zhao QH, Deng HF, Scharff MD. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res 2000;60:7008-13.
29. Popkov M, Sidrac-Ghali S, Lusignan Y, Lemieux S, Mandeville R. Inhibition of tumour growth and metastasis of human fibrosarcoma cells HT-1080 by monoclonal antibody BCD-F9. Eur J Cancer 2001;37:2484-92.
30. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: pre-clinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44:610-7.
31. Winthrop MD, DeNardo SJ, Albrecht H, et al. Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy. Clin Cancer Res 2003;9:3845-53S.
32. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713.
33. Adams GP, Shaller CC, Dadachova E, et al. A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004;64:6200-6.
34. Schoonjans R, Willems A, Schoonooghe S, et al. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 2000;165:7050-7.
35. Goel A, Colcher D, Baranowska-Kortylewicz J, et al. Genetically engineered tetravalent single-chain Fv of the pancarcmoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res 2000;60:6964-71.
36. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001;248:47-66.
37. Power BE, Doughty L, Shapira DR, et al. Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci 2003;12:734-47.
38. Olafsen T, Tan GJ, Cheung CW, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004;17:315-23.
39. Reff ME, Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 2001;40:25-35.
40. Koppe MJ, Bleichrodt RP, Soede AC, et al. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004;45:1224-32.